Introduction
Hepatocellular carcinoma (HCC) is the one of the most common lethal cancers and the second leading cause of cancer mortality worldwide. 1 HCC is associated with poor prognosis, and the incidence of HCC is increasing in many countries. 2 Therefore, it is very important to identify prognostic factors correlated with clinical outcomes. Several staging systems were proposed in the past years, including the Barcelona Clinic Cancer (BCLC) staging system, 3 the American Joint Committee on Cancer (AJCC) TNM staging system, 4 the Japan Integrated Staging Score, 5 and the Hong Kong Liver Cancer staging system. tumors predicting a worse prognosis in most cases, it has been included in most surgical staging systems for HCC. [7] [8] [9] However, several studies reported controversial results. [10] [11] [12] Because of the negative results reported in these studies, tumor size was excluded from the staging criteria in the latest 6th and 7th editions of the AJCC TNM staging system for HCC. 12 These conflicting results from the literature exist because data on the diameter of tumor size as a prognostic factor for HCC are limited.
We hypothesized that tumor size is useful for predicting the prognosis of HCC patients. To test this hypothesis, we analyzed the correlation between tumor size and pathological grade, tumor progression, and the selection of treatment using the Surveillance, Epidemiology, and End Results (SEER) database. The relationship between tumor size and overall survival (OS) was investigated to prove our hypothesis that clinical tumor size at diagnosis can be used to estimate the OS of patients with HCC. Data from a population-based subset from the USA were used to examine the value of tumor size as a prognostic factor in patients undergoing different treatments for HCC.
Materials and methods

Data source and study population
The SEER database for 1973-2014 (April 2017 version) was searched for this study. The SEER program is sponsored by the National Cancer Institute. It collects cancer incidence and survival information from 18 population-based cancer registries; 28% of the US population (seer.cancer.gov/about/ overview.html) is covered. The demographic data, primary lesion location, tumor morphology, tumor stage at diagnosis, surgical treatment performed, and survival status of all patients diagnosed with specific cancers were methodically compiled by each registry. Hispanics, Native Americans, and Asians/Pacific Islanders were oversampled in the SEER program.
ICD for Oncology, 3rd edition (ICD-O-3) site code C22.0 and histologic type ICD-O-3 codes 8170-8175 were used to identify patients diagnosed with HCC between 1988 and 2014 from the SEER database (90,755 HCC patients). Those HCC patients diagnosed between 1973 and 1987 were excluded (4,878 patients) because of insufficient staging information. Patients diagnosed with unknown age or age <18 years (202 patients) and those diagnosed by death certificate or at the time of autopsy (2,088 patients) were excluded. Patients were excluded if their SEER historic stage A was blank(s), in situ, or unstaged (11,426 patients) . Cases with unknown race/ethnicity (270 patients) and unknown or not stated tumor size (16,079 patients) were also excluded. Finally, a total of 57,920 HCC patients matching the specified eligibility criteria were included in the analysis. Detailed exclusion criteria are shown in Figure 1 .
From an initial 57,920 HCC patients who met the selection criteria, 17,964 HCC patients with histological grade records met the eligibility criteria for further evaluation of the association between tumor size and pathological grade, and all initial samples had SEER stage A data. HCC patients with or without Surg Prim Site data were available for 16, 208 and 41,656 patients, respectively (Figure 1 ). Patients with incomplete follow-up were removed from the analysis of OS.
ethics statement
An independent ethics committee/institutional review board at the Affiliated Drum Tower Hospital of Nanjing University Medical School (China) approved the study. The study was performed in agreement with the Declaration of Helsinki. Informed patient consent is not needed when using data retrieved from the SEER database because de-identified data were used. The access permission to use the research data file in the SEER program was approved by the National Cancer Institute, USA (reference number 12444-Nov2016).
Definitions
Tumor size was defined as the maximum diameter of the cancer mass based on the priority in order of pathology results, operative observes, or medical imaging reports. Patients without defined tumor size or tumor size >20 cm were excluded. Patients with HCC for further assessment were separated into groups according to tumor size as follows: 0.1-2.0, 2.1-5.0, 5.1-10.0, and 10.1-20.0 cm.
To ensure a consistent staging classification system for HCC throughout the study period, we used the SEER historical stage A system for the classification. The SEER historical stage A system provides a compatible definition through the period. The more frequently used AJCC staging system was not feasible for the analysis of the datasets before it was adopted by the SEER database. The SEER historical stage A system sorts tumors into localized (tumor was limited to the organ), regional (tumor invaded adjacent tissues or had lymph node metastases), or distant (distant metastasis was observed).
Based on SEER site-specific surgery definitions, we focused on the type of surgical treatment. The different surgical treatments were grouped into the following categories: no surgery performed, tumor-directed treatment, hepatic resection or lobectomy performed, and hepatectomy or transplant 
statistical analysis
Descriptive statistics were calculated for all demographic variables included in the analysis and rendered as proportion (%) and frequency (n) for each categorical variable. For continuous variables, mean and SD were used. Patient race was classified into White, Black, Asian (Asian/ Pacific Islander), and Native American (American Indian/Alaska native) groups based on the SEER coding manual. Other factors of interest were age, sex, and years since diagnosis. The selection of variables was determined by our medical knowledge and reading previous literatures. The associations of tumor size with pathological grade, SEER historic stage A, and selection of surgery were evaluated by using logistic regression analysis. Categorical variables were compared between different tumor size subgroups using Pearson's chisquared test. Patients diagnosed with HCC between 1988 and 2014 were retrieved for the measurement of OS rates and HRs. Five-year survival was calculated for OS and stratified by tumor size. Kaplan-Meier estimates of survival were stratified by tumor size, and treatment was analyzed using the log-rank test. Multivariable analysis of OS was performed using the Cox proportional hazards model. Results were identified as statistically significant at P≤0.05, corresponding to 95% CI. All statistical analyses were performed using SPSS software, version 22 (SPSS Inc., IBM Corporation, Chicago, IL, USA).
Results
Patient characteristics
Based on the patient exclusion criteria described above, 57,920 patients with HCC were retrieved from the SEER database and analyzed. The characteristics of the final study population are presented in Table 1 . The mean age (±SD) was 63.47±11.60 years, and 76% were men and 24% were women. The majority of HCC cases were in the age group of 55-64 years (34%). Most patients were White (67%), and the next largest group was Asian/Pacific Islanders (19%), followed by Black (13%). Median tumor diameter was 5.97 cm (range 0.1-20.0). Only 1% of the tumors had a diameter larger than 20 cm. Histological confirmation of the tumor was not available in 34,985 patients in the study group, and most HCC tumors (57%) were localized. After 1998, detailed treatment information was available for HCC patients. Most association between tumor size and grade (Table  S2) . Tumor size was an independent predictor of HCC stage (OR, 3.199; 95% CI, 3.091-3.312; P<0.001) was revealed by logistic regression analysis. Figure 2C ). In addition, there were differences in the type of treatment according to tumor size among patient groups that received any form of treatment for HCC ( Figure 2D To determine the value of primary tumor size as a prognostic factor in patients with HCC, we further investigated the association between OS and tumor size in the final study population. The 5-year OS rate of the entire group was 9.5%. For small size tumors (0.1-2 cm), the 5-year survival rate was 19.2% (Table 2 ). Survival decreased with increasing tumor size. Among 32,406 patients with localized HCC only, the 5-year OS rate was 13.7%; it was 21.9% for patients with tumors ≤2 cm in diameter, decreasing to 14.3% vs 9.2% vs 7.7% for patients with tumor sizes 2.1-5.0 vs 5.1-10.0 vs 10.1-20.0 cm, respectively. OS rate was similar across tumor size categories in patients with regional invasion. The relationship between HCC tumor size and OS stratified by SEER historic stage A is shown in Figure 3A .
survival in patients who underwent surgery A total of 16,581 patients received surgical resection treatment. The 5-year OS rate was 23.8% after surgery compared with 4.0% in patients who did not receive surgery (Table S3) Figure 3B . 
Predictors of hCC survival
Discussion
In the present study, analysis of population-based cancer registry data from the United States identified tumor size as an independent risk factor for the survival of patients with HCC and was associated with HCC differentiation, stage, and selection of treatment. Larger tumor size was associated with less differentiated tumors, more advanced stage, and lower survival compared with smaller tumor size groups. This finding may influence staging and treatment decisions in HCC.
As an important prognostic factor in HCC, tumor size is included in several staging systems such as the 6th and 7th editions of the AJCC TNM staging system, 12,13 Japan TNM staging system by the liver cancer study group, 8 and Hong Kong HCC staging system. 5 However, the negative correlation between tumor size and other critical adverse prognostic factors such as vascular invasion, poorly differentiated tumors, and multiple lesions was reported in some large cohort studies. 11, 14 Thus, the significance of tumor size at diagnosis as a prognostic factor for HCC remains controversial . 15, 16 Hence, tumor size at diagnosis as a prognostic factor for HCC was excluded in the 6th and 7th editions of the AJCC TNM classification system. 17, 18 Several studies later downplayed the importance of tumor size at diagnosis by demonstrating its lack of significance as a prognostic factor for HCC. 19, 20 However, in the latest 8th edition of the AJCC TNM classification system, T1 is subdivided into T1a and T1b based on a cutoff size of 2 cm . 21 The importance of tumor cutoff sizes of 5 and 10 cm as independent prognostic factors of HCC remains controversial, and further clinical studies are needed to clarify the relationship between tumor size and outcome in HCC. The present study indicated that with a tumor cutoff size of 5 or 10 cm, OS differs significantly among groups regardless of stage or the type of surgery. These findings also suggest that tumor size has a significant effect on the 5-year survival rate after surgery in HCC.
The results of the present study indicate that even after surgery, tumor size is an independent risk factor for HCC survival. The 5-year survival rate was significantly higher in patients who underwent surgery than in those who did not undergo surgery (23.8% vs 4.0%). Therefore, tumor size may be an important factor for the prognosis of HCC patients after surgery, which is consistent with the results of previous studies.
HCC tumor size is associated with genetic changes and pathological features. 22, 23 For example, larger tumor size is associated with capsular invasion, tumor thrombi, satellite nodules, and noninvasive growth patterns. Moreover, larger HCC tumor size stimulates invasive behavior. 24 Thus, recurrence and metastasis may be more commonly observed in patients with large size HCC than in those with small size HCC. The patients with larger tumors associated with unfavorable HCC phenotypes may clarify why large size HCC did not confer a survival benefit after treatment compared with that in patients with small size HCC. 
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The present study had several limitations associated with its retrospective study characteristics and the use of a national cancer registry database. The SEER historical stage A system is different from the commonly used AJCC staging system and may have fewer clinical correlations. However, this classification system allowed the staging of HCC with consistent criteria throughout the study period. The SEER database is limited by its lack of central pathological review. However, previous reports showed good agreement between the cancer histological subtypes reported by the SEER database and histological reports assigned by independent reviewers. The SEER data are also limited in relation to the recording of chemotherapy use. The completeness of the records and the potential biases associated with reasons for the use of chemotherapy were illustrated previously. Records with missing values in this study were excluded; this may be the best approach available at present. Although this method diminishes selection bias and increases universality, the results must be interpreted with caution. Prospectively, risk stratification for predicting metastasis and survival of HCC patients will be improved by adding specific tumor cell phenotypes.
Conclusion
The results of the present study supported that tumor size at diagnosis is an independent prognostic factor for OS in HCC, regardless of tumor grade, stage, or selection of treatments. These results strongly suggest that the 8th edition of the AJCC TNM staging system was improved by the separation of early-stage HCC according to tumor size ≤2 or >2 cm. However, the present findings suggest that the HCC staging systems can be further improved by division into substages based on tumor cutoff sizes of 5 and/or 10 cm.
